QC Ware Develops Quantum Computing Solutions with Promethium Software for Pharma and Materials Industries
QC Ware has developed Promethium, a molecular design software for the pharmaceutical and materials industries, achieving over $1 million in bookings within its first year and attracting nearly 30 top-tier clients, including nine of the top 20 pharma companies. The company aims to innovate molecule development through fully 'in silico' methods, addressing complex simulation problems that competitors cannot solve, with a total addressable market estimated at $2 billion. Additionally, the Q2B Conference supports quantum startups and enhances visibility in the quantum technology sector.
Theia Market Signal Identification - AI Assisted
QC Ware, founded by former Air Force officer and private equity executive Johnson, emerged from a collaboration with NASA-Ames' quantum computing group. The company’s core product, Promethium, is a molecular design software utilized by pharmaceutical and materials companies, achieving over $1 million in bookings in its first year and attracting nearly 30 top-tier clients, including nine of the top 20 pharma companies.
QC Ware aims to innovate by enabling fully 'in silico' molecule development, reducing reliance on traditional experimentation. The total addressable market for its SaaS offering is estimated at $2 billion, with potential expansion into larger markets.
The company distinguishes itself from competitors by solving complex simulation problems that other software cannot. Additionally, the Q2B Conference, which supports quantum startups, is positioned as a major industry event, fostering visibility and innovation in quantum technologies.
Comments